The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Novartis plans for 60 regulatory filings during 2019-2021
Asthma, Blockbusters, Chronic Lymphocytic Leukemia (CLL), European Medicines Agency, FDA, Multiple Sclerosis, Neovascular Age-Related Macular Degeneration (nAMD), Potential Blockbusters, Product Launches, Product Pipelines, Radioligands, Research & Development, Spinal Muscular Atrophy (SMA)Swiss pharma giant Novartis announced plans to seek regulatory approval for 60 new treatments between 2019 and 2021.